Industry News
Pharmaceutical Industry News
The approval for Lunsumio Velo…
The approval for Lunsumio Velo allows Roche to fill an administration convenience gap with AbbVie and Genmab's rival T-cell engager; all the while, the Swiss pharma has been touting the reduced burden of its fixed-duration
Incog BioPharma, a sterile…
Incog BioPharma, a sterile injectables CDMO, plans to shell out about $200 million to boost production capacity at its Fishers, Indiana, manufacturing site.
Samsung Bio’s U.S. subsidiary…
Samsung Bio’s U.S. subsidiary will pay $280 million to acquire GSK’s Human Genome Sciences and its two pharmaceutical manufacturing plants at a campus in Rockville, Maryland. The site, which will mark Samsung Bio’s first for
¿Por cuánto tiempo puedes tomar antidepresivos?
Estos medicamentos, creados para hacerte sentir bien, son difíciles de dejar sin la guía de un psiquiatra. Pedimos la opinión de varios expertos a este respecto.
Trump Announces Pricing Deals With Nine Drugmakers
The companies were the latest to agree to sell drugs to Medicaid and directly to consumers at discounted prices. President Trump said he would soon begin similar negotiations with health insurers.
F.D.A. Turmoil Keeps Spotlight on Its Commissioner
The agency’s high-level turnover and conflicting policy decisions on drug oversight have fueled concerns about the leadership of Dr. Marty Makary.
Updates on DTC advertising and DTP…
Updates on DTC advertising and DTP programs, as well as special reports, event coverage and, of course, news bulletins from the ever-evolving GLP-1 front all made the list of our most-read stories in 2025.
After a series of ownership…
After a series of ownership changes, Andexxa is slated to be pulled from the market in the coming days. The FDA said it "considers the risks of the product to outweigh its benefits."
The Elevidys-related manufacturing…
The Elevidys-related manufacturing shortfalls were described in one of two Form 483s tied to FDA inspections that came before Catalent's layoff spree at its Maryland gene therapy manufacturing business.
Sixteen months after luring former…
Sixteen months after luring former Roche dealmaker James Sabry, M.D., Ph.D., out of retirement and signaling a shift in its business development approach, BioMarin has announced the largest transaction in the company’s 28-year history.
Amgen, Boehringer Ingelheim,…
Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Gilead Sciences, GSK, Merck & Co., Novartis, Roche and Sanofi have agreed with the White House to reduce the prices of certain prescription medicines in exchange for pharmaceutical tariff
As the FDA steadily churns out a…
As the FDA steadily churns out a stream of untitled letters chastising pharmaceutical advertisers’ direct-to-consumer materials, a commercial for Bristol Myers Squibb’s Cobenfy is taking its turn in the hot seat.
Cybin is shedding its old…
Cybin is shedding its old identity, evolving into Helus Pharma as part of changes that will see its shares move to a different stock exchange.
Fierce reporters break down the…
Fierce reporters break down the forces that shaped biopharma and healthcare in 2025 and what lies ahead in 2026.
Alvotech and Teva’s Eylea…
Alvotech and Teva's Eylea biosimilar has been under FDA review for much of this year. Back in February, the companies said they expected a decision by the end of 2025.
Pharma marketers enter 2026 asking…
Pharma marketers enter 2026 asking where DTC fits in the DTP era. That question, which few foresaw 12 months ago, reflects the fast rise of direct-to-patient programs. The programs are changing how patients access medicines—and
President Trump Reclassifies Marijuana With Executive Order
Marijuana was downgraded from a Schedule I drug to a Schedule III drug on Thursday. The reclassification does not legalize cannabis, but it does ease restrictions on the substance and allows for more research.
Amid rapidly evolving media…
Amid rapidly evolving media consumption habits and a federal push to limit direct-to-consumer drug advertising, pharma companies in 2026 and beyond are on track to continue their migration away from linear TV as the primary
Daiichi Sankyo scored a key FDA…
Daiichi Sankyo scored a key FDA approval for Enhertu in first-line HER2-positive breast cancer but paused a phase 3 trial of its Merck-partnered ADC due to unexpected patient deaths. Takeda plans to file its TYK2
As Medtronic begins rolling out a…
As Medtronic begins rolling out a recently FDA-cleared diabetes management system combining its MiniMed 780G insulin pump and Abbott’s Instinct glucose sensor, the medtech giant has launched a new campaign to promote the duo.